Bal Pharma Limited

10.08.2016

Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub : Out Come of the Board Meeting.

As already informed to the exchanges, Board of Directors of the Company met today and *inter alia* transacted the following business;

1. Approved the Un-audited financial results of the Company for the quarter ended 30.06.2016. A copy of the approved financial results along with the report on the Limited Review conducted by the statutory auditors of the Company is enclosed with this intimation.,

2. Convened 29th Annual General Meeting of the Company on 22nd September, 2016 at 10.30 AM at ESV Hall, Bharatiya Vidya Bhavan, Race Course Road, Bangalore-560001.

3.Decided to close the Register of Members and Share Transfer Books of the Company from 18th September, 2016 to 22nd September, 2016 (both days inclusive).

Please take this intimation on record.

For Bal Pharma Limited

BAL PHARMA LTD. BANGALORE

Shailesh Siroya
Managing Director.

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58
Email : balpharma@vsnl.com Website : www.balpharma.com

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bangalore - 560 099. Ph: 41570813 / 19 Fax: 41570820

BAL PHARMA LIMITED

Regd.Office: 21-22 Bommasandra Industrial Area,Anekal Taluq,Bangalore 560 099
Phone : 080 41379500 Fax : 080 22354057 email :secretarial@balpharma.com

STANDALONE/CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2016

CIN: L85110KA1987PLC008368

(Rs in Lakhs except EPS data

Sr. No:	Particulars	STANDALONE				CONSOLIDATED			
		Quarter ended			Year Ended	Quarter ended			Year Ended
		30 Jun 16 Unaudited	30 Jun 15 Unaudited	31 Mar 16 Audited	31 Mar 16 Audited	30 Jun 16 Unaudited	30 Jun 15 Unaudited	31 Mar 16 Audited	31 Mar 16 Audited
PART I									
1	**Income from Operations**								
	a) Net Sales/Income from operations (Net of Excise Duty)	4,292.40	4,052.59	5,362.25	19,416.15	4,396.64	4,055.24	5,388.13	19,482.16
	b) Other Operating Income	65.20	74.13	93.11	349.50	65.20	74.13	93.11	349.50
	Total Income from Operations (net)	**4,357.60**	**4,126.72**	**5,455.36**	**19,765.65**	**4,461.85**	**4,129.37**	**5,481.24**	**19,831.66**
2	**Expenses**								
	a) Consumption of Raw Materials/ Packing Material	2,052.65	2,138.16	2,812.87	9,767.82	2,052.65	2,138.16	2,812.87	9,767.82
	b) Purchase of Stock in Trade	174.33	139.95	273.50	738.67	180.18	141.26	275.02	757.75
	c) Increase/decrease in stock in trade and WIP	(120.31)	(183.65)	(4.14)	(37.72)	(127.50)	(183.65)	(11.71)	(47.48)
	d) Employee Cost	945.26	790.41	958.84	3,567.19	1,031.14	805.57	1,039.92	3,734.55
	e) Depreciation and amortisation expenses	149.32	159.57	224.38	697.42	150.05	160.36	225.36	700.90
	f) Other Expenditure	961.59	902.68	1,131.92	4,015.79	992.73	911.14	1,181.89	4,133.73
	g) Total	**4,162.83**	**3,947.12**	**5,397.37**	**18,749.16**	**4,279.24**	**3,972.84**	**5,523.35**	**19,047.27**
3	Profit from Operations before other Income, finance costs and Exceptional items(1-2)	**194.76**	**179.60**	**57.99**	**1,016.48**	**182.60**	**156.53**	**(42.11)**	**784.39**
4	Other Income	77.36	16.54	42.39	149.61	77.36	16.54	24.09	128.33
5	Profit before finance cost and Exceptional items (3+4)	**272.13**	**196.14**	**100.38**	**1,166.09**	**259.96**	**173.07**	**(18.02)**	**912.72**
6	Finance Costs	193.57	130.02	209.22	647.66	193.62	130.03	209.26	647.77
7	Profit after finance cost but before Exceptional items	78.56	66.12	(108.83)	518.44	66.34	43.04	(227.28)	264.95
8	Exceptional items	-	-	-	-	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax (7-8)	78.56	66.12	(108.83)	518.44	66.34	43.04	(227.28)	264.95
10	Tax expenses	19.40	17.86	68.50	237.83	19.40	17.86	69.68	239.01
11	Net Profit /Loss from ordinary Activities after Tax	59.16	48.26	(177.34)	280.60	46.94	25.18	(296.97)	25.93
12	Extra ordinary items	-	-	-	-	-	-	-	-
13	Net Profit / Loss for the period	59.16	48.26	(177.34)	280.60	46.94	25.18	(296.97)	25.93
14	Minority interest					(3.63)	(1.92)	17.75	(114.60)
15	Net Profit / Loss after taxes and minority interest	59.16	48.26	(177.34)	280.60	50.56	27.10	(314.72)	140.53
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,417.24	1,287.24	1,287.24	1,287.24	1,417.24	1,287.24	1,287.24	1,287.24
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year								
16	**Earnings Per Share** (of Rs 10 each) (Not annualised)								
	a) Basic	0.42	0.37	(0.14)	2.18	0.04	0.21	(0.24)	1.73
	b) Diluted	0.42	0.37	(0.14)	2.18	0.04	0.21	(0.24)	1.73

PART II

A	**Particulars of Shareholding**								
	1) Public shareholding								
	- Number of Shares	78,86,570	65,86,570	65,86,570	65,86,570	78,86,570	65,86,570	65,86,570	65,86,570
	- Percentage of shareholding	55.65	51.17	51.17	51.17	55.65	51.17	51.17	51.17
	2) Promoters & Promoter group Shareholding								
	a) Pledged / Encumbered								
	- Number of Shares	-		-	-	-		-	
	- Percentage of shareholding	-		-	-	-		-	
	b) Non-encumbered								
	- Number of Shares	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802
	- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%
	- Percentage of shareholding (as a % of total share capital of the company)	44.35	48.83	48.83	48.83	44.35	48.83	48.83	48.83

PART III

B Investor Complaints

Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Diposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

Notes:

1 The above unaudited financial results as reviewed by the Audit Committee were approved by the Board of Directors at its meeting held on 10.8.2016.

2 Statutory Auditors have conducted Limited Review on the unaudited financial results for the quarter ended 30.06.2016.

3 Previous year figures were regrouped/rearranged to conform to the classification of current year.

4 As the Company deals with single product i. e pharmaceuticals, segment wise figures are not furnished.

Bangalore
10 Aug 16

By the order of Board of Directors

Shailesh Siroya
Managing Director.

BAL PHARMA LTD. BANGALORE

T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

CA T.D. JAIN B.Com., F.C.A.
CA DHANPAL I SAKARIA
B.Com. F.C.A.

34, Keshava Nivas, 3rd Floor
First Main, Gandhinagar
Bangalore-560 009
Phone : 22356135, 22356137
Telefax : 080-22356136
E-mail : ostawaljain@gmail.com

LIMITED REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIALS RESULTS FOR THE QUARTER ENDED JUNE 30, 2016

To
Board of Directors
Bal Pharma Limited

We have reviewed the unaudited financial results of BAL PHARMA LIMITED ("the company") for the quarter ended June 30, 2016 which are included in the accompanying statement of unaudited financial results for the quarter ended June 30 2016 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA
Chartered Accountants
Firm registration no: 002491S

DHANPAL I SAKARIA
Partner
M No: 213666

Place: Bangalore
Date: 10/08/2016

T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

CA T.D. JAIN B.Com., F.C.A.
CA DHANPAL I SAKARIA
B.Com., F.C.A.

34, Keshava Nivas, 3rd Floor
First Main, Gandhinagar
Bangalore-560 009
Phone : 22356135, 22356137
Telefax : 080-22356136
E-mail : ostawaljain@gmail.com

LIMITED REVIEW REPORT ON THE CONSOLIDATED UNAUDITED FINANCIALS RESULTS FOR THE QUARTER ENDED JUNE 30, 2016

To
Board of Directors
Bal Pharma Limited

We have reviewed the consolidated unaudited financial results of BAL PHARMA LIMITED ("the company") and its subsidiaries (hereafter referred to as the "Group") for the quarter ended June 30, 2016 which are included in the accompanying Unaudited Consolidated Financial results for the quarter ended June 30 2016 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the" "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

The statement includes the financial results of following entities:

Lifezen Healthcare Private Limited	Subsidiary
Balance Clinics LLP	Subsidiary
Bal Research Foundation	Subsidiary

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results, prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA
Chartered Accountants
Firm registration no: 002491S

DHANPAL I SAKARIA
Partner
M No: 213666

Place: Bangalore
Date: 10/08/2016